Disease · MONDO_0015447
differentiated thyroid carcinoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. differentiated thyroid carcinoma. Diseases, record MONDO_0015447. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0015447
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
differentiated thyroid cancer, differentiated thyroid gland cancer, differentiated thyroid gland carcinoma, papillary or follicular thyroid carcinoma, thyroid gland differentiated carcinoma, thyroid gland well differentiated carcinoma, well differentiated thyroid carcinoma, well differentiated thyroid gland carcinoma, well-differentiated thyroid cancer
- Open Targets
- Highest stage of its drugs
- Approval, for 3 of its 72 drugs, from ClinicalTrials.gov and DailyMed
- Open Targets
Drugs72
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| LENVATINIB | CHEMBL1289601 | Small molecule | Approval | ClinicalTrials.gov | 15 | 15 | 15 | Drugs and targets |
| LEVOTHYROXINE SODIUM | CHEMBL2103741 | Small molecule | Approval | DailyMed | 2 | 0 | 0 | Drugs and targets |
| LIOTHYRONINE SODIUM | CHEMBL1201119 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| SORAFENIB | CHEMBL1336 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| TRAMETINIB | CHEMBL2103875 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| DABRAFENIB | CHEMBL2028663 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CABOZANTINIB | CHEMBL2105717 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| IODINE | CHEMBL1201225 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 0 | Drugs and targets |
| LEVOTHYROXINE | CHEMBL1624 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| THYROTROPIN | CHEMBL1201532 | Phase 3 | ClinicalTrials.gov | 3 | 3 | 1 | Drugs and targets |
1 to 10 of 72
See all 72 drugsTargets137
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| KDR | Vascular endothelial growth factor receptor | 14 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/3791 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 11 | Vascular endothelial growth factor receptor 3 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2324 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 10 | Vascular endothelial growth factor receptor 1 inhibitor; Vascular endothelial growth factor receptor inhibitor | Approval | https://conductscience.org/library/genes/2321 | Drugs and targets |
| PDGFRB | Platelet-derived growth factor receptor | 9 | Platelet-derived growth factor receptor beta inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/5159 | Drugs and targets |
| KIT | Mast/stem cell growth factor receptor Kit | 8 | Stem cell growth factor receptor inhibitor | Phase 3 | https://conductscience.org/library/genes/3815 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 7 | Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| PDGFRA | Platelet-derived growth factor receptor | 7 | Platelet-derived growth factor receptor alpha inhibitor; Platelet-derived growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/5156 | Drugs and targets |
| FGFR1 | Fibroblast growth factor receptor | 5 | Fibroblast growth factor receptor 1 inhibitor; Fibroblast growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2260 | Drugs and targets |
| RET | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET | 5 | Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Tyrosine-protein kinase receptor RET inhibitor | Phase 3 | https://conductscience.org/library/genes/5979 | Drugs and targets |
| BRAF | Serine/threonine-protein kinase B-raf | 4 | Serine/threonine-protein kinase B-raf inhibitor | Phase 3 | https://conductscience.org/library/genes/673 | Drugs and targets |
1 to 10 of 137
See all 137 targetsTrials79
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 6 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00984282 | Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer | Phase 3 | 417 | 2013-12-10 | Thyroid Neoplasms | SORAFENIB | Its record names the disease | ClinicalTrials.gov |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) | Phase 3 | 392 | 2016-12-12 | Thyroid Cancer | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02702388 | A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile | Phase 2 | 241 | 2021-01-11 | Thyroid Cancer | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00625846 | Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer | Phase 2 | 152 | 2020-02-26 | Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma | PAZOPANIB HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02304757 | 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis | Not applicable | 142 | 2021-10-18 | Differentiated Thyroid Cancer, Osteoporosis | ALENDRONATE SODIUM | Its record names the disease | ClinicalTrials.gov |
| NCT01208051 | Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer | Phase 1/2 | 127 | 2021-07-15 | Refractory Differentiated Thyroid Gland Carcinoma, Refractory Thyroid Gland Follicular Carcinoma, Refractory Thyroid Gland Hurthle Cell Carcinoma, Refractory Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Carcinoma | CEDIRANIB MALEATE, LENALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00784303 | Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology | Phase 2 | 117 | 2019-08-01 | Thyroid Cancer | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02432274 | Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma | Phase 1/2 | 117 | 2020-09-17 | Tumors, Solid Malignant Tumors, Osteosarcoma, Differentiated Thyroid Cancer (DTC) | ETOPOSIDE, IFOSFAMIDE, LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00381641 | Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery | Phase 2 | 63 | 2017-09-15 | Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7, Thyroid Gland Oncocytic Carcinoma, Unresectable Thyroid Gland Carcinoma | SUNITINIB MALATE | Its record names the disease | ClinicalTrials.gov |
| NCT02973997 | Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) | Phase 2 | 57 | 2023-10-24 | Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Recurrent Thyroid Gland Follicular Carcinoma, Recurrent Thyroid Gland Papillary Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Follicular Carcinoma AJCC v7, Stage III Thyroid Gland Papillary Carcinoma AJCC v7, Stage IV Thyroid Gland Follicular Carcinoma AJCC v7, Stage IV Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVA Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVB Thyroid Gland Papillary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Follicular Carcinoma AJCC v7, Stage IVC Thyroid Gland Papillary Carcinoma AJCC v7, Tall Cell Variant Thyroid Gland Papillary Carcinoma, Thyroid Gland Hurthle Cell Carcinoma, Unresectable Differentiated Thyroid Gland Carcinoma, Unresectable Thyroid Gland Carcinoma | LENVATINIB, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 79
See all 79 trialsComparisons in its trials13
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Lenvatinib 24 mg vs Lenvatinib 18 mg: deaths from any cause | 11 of 75 | 19 of 77 | 152 | NCT02702388 | Trial comparisons |
| Lenvatinib 24 mg vs Lenvatinib 18 mg: serious adverse events | 26 of 75 | 35 of 77 | 152 | NCT02702388 | Trial comparisons |
| 99Tc-MDP vs Fosamax: deaths from any cause | 0 of 70 | 0 of 72 | 142 | NCT02304757 | Trial comparisons |
| 99Tc-MDP vs Fosamax: serious adverse events | 0 of 70 | 0 of 72 | 142 | NCT02304757 | Trial comparisons |
| DTC Cohort vs MTC Cohort: deaths from any cause | 44 of 58 | 37 of 59 | 117 | NCT00784303 | Trial comparisons |
| DTC Cohort vs MTC Cohort: serious adverse events | 32 of 58 | 42 of 59 | 117 | NCT00784303 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Objective Response Rate, Assessed Using the Response Evaluation Criteria in Solid Tumors (RECIST) | 9 of 38 | 7 of 25 | 63 | NCT00381641 | Trial comparisons |
Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: Incidence of Toxicity, Graded According to the Common Terminology Criteria for Adverse Events Version 3.0 | 38 of 38 | 24 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: deaths from any cause | 21 of 38 | 5 of 25 | 63 | NCT00381641 | Trial comparisons |
| Sunitinib Malate-Radioactive Iodine Refractory Subgroup vs Sunitinib Malate-Metastatic Medullary Subgroup: serious adverse events | 17 of 38 | 12 of 25 | 63 | NCT00381641 | Trial comparisons |
1 to 10 of 13
See all 13 comparisons in its trialsPapers from its trials67
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0015447
GET https://conductscience.org/api/diseases/v1/MONDO_0015447/drugs?page=2